PD-L1/PD-1 axis as a potent therapeutic target in breast cancer

Bastaki, S and Irandoust, M and Ahmadi, A and Hojjat-Farsangi, M and Ambrose, P and Hallaj, S and Edalati, M and Ghalamfarsa, G and Azizi, G and Yousefi, M and Chalajour, H and Jadidi-Niaragh, F (2020) PD-L1/PD-1 axis as a potent therapeutic target in breast cancer. Life Sciences, 247. p. 117437. ISSN 00243205

Full text not available from this repository.
Official URL: https://www.sciencedirect.com/science/article/pii/...


Although both the incidence and the mortality rate of breast cancer is rising, there is no potent and practical option for the treatment of these patients, particularly in advanced stages. One of the most critical challenges for treatment is the presence of complicated and extensive tumor escape mechanisms in the tumor microenvironment. Immune checkpoint molecules are of the main immunosuppressive mechanisms used by cancerous cells to block anti-cancer immune responses. Among these molecules, PD-1 (Programmed cell death) and PD-L1 (programmed cell death-ligand 1) have been considered as worthy therapeutic targets for breast cancer therapy. In this review, we intend to discuss the immunobiology and signaling of the PD-1/PD-L1 axis and highlight its importance as a worthy therapeutic target in breast cancer. We believe that the prognostic value of PD-L1 depends on the breast cancer subtype. Moreover, the combination of PD-1/PD-L1 targeting with immune-stimulating vaccines can be considered as an effective therapeutic strategy in breast cancer.

Item Type: Article
Uncontrolled Keywords: Breast cancer Immune checkpoint Immunotherapy PD-1 PD-L1
Subjects: Q Science > QR Microbiology > QR180 Immunology
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Research Center > Persian Gulf Marine Biotechnology Research Center
Depositing User: خدیجه شبانکاره
Date Deposited: 22 Dec 2020 10:27
Last Modified: 22 Dec 2020 10:27
URI: http://eprints.bpums.ac.ir/id/eprint/9045

Actions (login required)

View Item View Item